Page 9 - Randomized Phase News Today

/PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data for lecanemab (BAN2401), an investigational anti-amyloid...

STOCKHOLM, July 26, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Aß)

Today, Novo Nordisk announced results of once-weekly Sogroya® (somapacitan) injection in helping children achieve growth targets of annualised height velocity (AHV).1 These phase 3 results from the REAL 4 study, in prepubertal children with growth hormone deficiency (GHD), were presented today at the Endocrine ...

NICE Recommends Astellas’ EVRENZO▼™ (roxadustat) For Adults With Symptomatic Anaemia Associated With Chronic Kidney Disease EVRENZOTM (roxadustat) is the first hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor to be recommended by NICE1Over 75,000 adults in England and Wales living with...

Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective est...

Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective

Investegate announcements from NuCana plc, NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patientsPFS rate at 12 months with elacestrant was 22.32% vs. 9.42%

Researchers reported findings that assessed the safety and efficacy of Ensitrelvir among patients with asymptomatic or mild-to-moderate SARS-CoV-2 infection in Japan.